We have an interest in B-cell lymphomas and are focusing on scenarios that are associated with poor outcome such as early progression after treatment, transformation to aggressive lymphoma and relapse in the central nervous system. We are applying cutting-edge tools to primary patient samples to unravel tumour heterogeneity and to develop novel, innovative biomarkers to predict outcome in lymphoma. Furthermore, we are leveraging novel findings from discovery platforms to elucidate mechanisms of lymphoma pathogenesis, tumour evolution and treatment resistance. Our ultimate goal is to improve patient outcomes through a better understanding of the diversity of responses to treatment and by tailoring therapy to each individual patient.
Robert Kridel, MD, MPH, PhD
Clinician Scientist, Princess Margaret Cancer Centre